PLAINSBORO, N.J., Jul 9, 2010 (GlobeNewswire via COMTEX) — Integra LifeSciences Holdings Corporation(IART 36.72, -0.41, -1.10%) announced today the launch of DuraGen Plus(R) Dural Regeneration Matrix – Spinal Matrix, an absorbable and sutureless collagen onlay indicated as a dura substitute for the repair of dura mater.
Integra developed the first onlay collagen graft for dural repair in 1999 and is the market leader in providing graft materials for sutureless closure of dural defects in the United States.
The dura mater is a tough, fibrous membrane that surrounds and protects the tissues of the brain and spinal cord. When the dura mater is cut or torn, it must be repaired, either by suturing or applying a dural graft, to prevent cerebrospinal fluid (CSF) leaks. Dural defects may be repaired using several techniques, including commercially available dural graft substitutes. Surgeons may be able to repair the dura mater more efficiently when using graft substitutes that do not require sutures, such as DuraGen Plus(R) Dural Regeneration Matrix – Spinal Matrix.
“DuraGen Plus(R) Dural Regeneration Matrix – Spinal Matrix demonstrates Integra’s ongoing commitment to provide surgeons with the most innovative technology, help increase confidence in patient treatment, and save valuable time in the operating room,” said John Winge, Executive VP, Sales and Marketing, Integra Spine.
The DuraGen Plus(R) Dural Regeneration Matrix – Spinal Matrix is distributed by Integra Spine’s independent distributor network. Integra Spine is a leading provider of fusion implants and orthobiologics products. Please visit www.integraspine.com for more information.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. The company’s products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. Please visitwww.integralife.com for more information.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of DuraGen Plus(R) and DuraGen(R) products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.